A Phase I study combining natural killer cells with high-dose chemotherapy and stem cell transplantation showed promising results in treating multiple myeloma. The treatment resulted in no toxicity or graft-versus-host disease, offering a potential new approach for patients.
Researchers found that losing CD73 enzyme promotes tumor growth and progression in endometrial cancer by disrupting adenosine signaling, which normally regulates tissue function. The study provides new insights into the role of CD73 in cancer development.
A multi-center study found ibrutinib to be more effective than chlorambucil in treating CLL, with a 97.8% overall survival rate after two years compared to 85.3%. Ibrutinib also improves hemoglobin and platelet levels.
A comprehensive study led by MD Anderson Cancer Center researchers found complete surgical excision of the implant and surrounding capsule to be the most effective treatment approach for BI-ALCL, with significant improvements in event-free survival and overall survival compared to radiation therapy and chemotherapy.
Researchers found p53 blocks PDL1 protein, which halts immune attack on lung cancer cells. High levels of p53 and miR-34a increase survival rates in patients with lung cancer.
A study at MD Anderson Cancer Center reveals that increased methylation of epidermal growth factor receptors (EGFR) leads to resistance to cetuximab antibody therapy, resulting in poorer clinical outcomes and higher recurrence rates. The study also found that expression of methylation-defective EGFR reduces tumor growth in mice.
A study at MD Anderson Cancer Center found that suppressing epithelial-to-mesenchymal transition (EMT) in combination with gemcitabine may boost the drug's effectiveness against pancreatic cancer. EMT suppression leads to impaired sensitivity to chemotherapy, causing poor prognosis and metastasis.
A genetic biomarker called loss of heterozygosity (LOH) predicts which patients with premalignant mouth lesions are at highest risk of developing oral cancer. The study found that LOH-positive patients had a three-year cancer-free survival rate of 74% compared to 87% for LOH-negative patients.
A new study from MD Anderson Cancer Center finds that high-temperature cooking of meat, particularly barbecuing and pan-frying, increases the risk of renal cell carcinoma. Individuals with certain genetic mutations are more susceptible to this risk, highlighting the importance of reducing meat consumption, especially at high temperatures.
Researchers found that tumor suppressor protein PTEN is lost in brain cancer cells but restored once they migrate to other organs. This reversible loss enables brain metastases growth and protects against cell death.
A study published by the University of Texas M. D. Anderson Cancer Center found that intensity modulated radiation therapy (IMRT) reduced severe pneumonitis and improved chemotherapy tolerance in patients with locally advanced non-small cell lung cancer compared to conventional radiation therapy.
A study led by University of Texas M. D. Anderson Cancer Center researchers identified EphB4 as a trigger for tumor growth via STAT3 protein regulation, linking cancer anemia treatment to tumor progression.
Researchers have discovered a new approach to understanding cancer mechanisms, biomarkers, and treatments using RNA editing events. The study, published in Cancer Cell, found that specific RNA editing processes could selectively affect drug sensitivity and may lead to the development of targeted therapies.
The study found that everolimus improved progression-free survival by 52% and increased median progression-free survival by over seven months in patients with advanced, nonfunctional neuroendocrine tumors. The treatment was well-tolerated, with common side effects including aphthous ulceration, rash, diarrhea, fatigue, and infections.
Researchers at the University of Texas MD Anderson Cancer Center demonstrated a significant median overall survival benefit with nivolumab, increasing it to 25 months compared to 19.6 months for everolimus. The study also showed a higher objective response rate and fewer treatment-related adverse events with nivolumab.
A protein-coding gene called hnRNP K has been identified as a potential target for treating acute myeloid leukemia. The study found that expression of hnRNP K is significantly reduced in AML patients who carry a specific genetic deletion, suggesting it acts as a tumor suppressor.
Researchers found that generic heart medications, specifically nonselective beta-blockers, significantly improved overall survival among ovarian cancer patients. This is attributed to the ability of these drugs to block stress pathways involved in tumor growth and spread, with further research needed to explore their potential benefits.
Scientists have discovered a cytokine called MIF that regulates EGFR activation in the tumor microenvironment, promoting tumor progression. The findings could lead to new approaches in treating tumors by intervening in this self-regulating loop.
A study at the University of Texas MD Anderson Cancer Center found that CSN6 is overexpressed in colorectal cancer tissue samples, leading to poor survival rates. The biomarker's deregulation can lead to cancer development through cellular signaling pathways.
Women with early-stage breast cancer who receive a shorter course of whole breast radiation therapy experience less toxicity and improved quality of life compared to those who undergo a longer course of treatment. The study suggests that hypofractionated treatment should be considered as a starting point for discussion between patients...
Scientists at MD Anderson Cancer Center discovered the critical role of fumarase enzyme in DNA repair, revealing a key mechanism for reversing genetic damage leading to cancer and therapy resistance. The study's findings have potential implications for developing new cancer treatments by inhibiting DNA-PKs and fumarase.
Scientists at University of Texas MD Anderson Cancer Center identified EMT as a potential therapeutic target for reversing kidney disease and fibrosis. The study showed that inhibiting EMT in tubular epithelial cells can restore their health and function.
The MD Anderson Cancer Center has been selected as a Genome Characterization Center to analyze patient samples from multiple NCI programs. The center will focus on functional proteomics, enabling the study of protein expression and modification in cancer tumors.
Researchers found that 35% of patients with early-onset colorectal cancer (diagnosed before age 35) have a genetic disease, highlighting the need for genetic counseling to identify high-risk family members. Gene panel testing is recommended to uncover underlying mutations, allowing for preventive measures and earlier screening.
A new study by MD Anderson researchers found that protein 14-3-3 sigma opposes and reverses tumor-promoting metabolic programs in breast cancer. The study revealed that 14-3-3 sigma suppresses cancer glycosis, preventing tumors from converting glucose into pyruvate.
MD Anderson researchers discovered a breast tumor marker that predicts metastasis by analyzing the gene expression signature of mouse embryos. Tumors with similar signatures to six-day-old embryos were more prone to metastasize than those with adult-like signatures.
Researchers at MD Anderson Cancer Center have identified a potential non-invasive diagnostic tool for early pancreatic cancer detection. Glypican-1-enriched circulating exosomes were found to be present in small amounts of serum from patients with pancreatic cancer, showing high specificity and sensitivity. Early detection of pancreati...
Current blood cancer drug prices are too high to be considered cost-effective in the US, according to a recent MD Anderson Cancer Center study. The researchers found that 63% of 20 studies evaluated had costs per additional life-year higher than $50,000, indicating that current prices cannot be justified based on improved quality of life.
Researchers identified four melanoma subtypes, including BRAF, RAS, NF1 and Triple-WT, through analysis of 331 patient samples. These subtypes share common signaling pathways but differ in activation, suggesting potential for targeted therapies.
The study found that breast-conserving therapy (BCT) is being used more widely, with a steady increase in rates over the last 13 years. However, disparities persist, particularly among patients without insurance or those living far from treatment facilities.
A recent study by MD Anderson researchers identified DAPK1 as a novel therapeutic target for breast and other cancers with TP53 mutations. High levels of DAPK1 are associated with poor prognosis and increased cancer growth in these tumors.
Researchers found that mutations in ARID1a gene sensitize certain tumors to PARP inhibitor drugs, allowing for more effective treatment options. The study highlights the importance of using genomic information to guide cancer therapy and identify precise treatments for individual patients.
A new way of classifying brain cancers has been found, with striking molecular differences between various forms of gliomas. This discovery could lead to more precise diagnosis and patient management.
Researchers discovered that TLR4 can function as a growth suppressor in wild-type TP53 cells but promotes growth in TP53 mutant cells. This balance affects survival rates and treatment outcomes.
A large study has found that whole brain radiation therapy (WBRT) significantly worsens cognitive function compared to radiosurgery, and should no longer be used in the adjuvant setting after radiosurgery. WBRT's side effects include hair loss, fatigue, and significant interruptions in systemic therapy.
A study has identified a possible new combination chemotherapy regimen for patients with advanced metastatic castrate-resistant prostate cancer. The treatment, combining cabazitaxel and carboplatin, significantly extended progression-free survival by 2.3 months compared to single-agent therapy.
Jim Allison's pioneering work on T-cell response mechanisms led to the development of ipilimumab, a melanoma treatment that has shown unprecedented results in survival rates. His research continues to open new avenues for cancer treatment through immune checkpoint blockade.
Researchers at MD Anderson Cancer Center have identified a biomarker that may boost the response to chemotherapy in patients with ovarian cancer. The study found that miR-506 was associated with improved responses to chemotherapy drugs cisplatin and olaparib, leading to better overall survival.
A recent study from the University of Texas MD Anderson Cancer Center suggests that profiling normal DNA provides an opportunity to identify inherited mutations critical for patients and their families. Researchers sequenced tumor and normal DNA from patients with advanced cancer, identifying germline mutations in nearly all cases.
A phase III randomized clinical trial suggests that Stereotactic Ablative Radiotherapy (SABR) is equally effective to surgery in treating operable stage I non-small cell lung cancer patients, with better survival rates and lower toxicity. SABR appears to be a suitable alternative for elderly and comorbidity-prone patients.
Researchers found that hepatitis B patients develop HCC at a younger age with more aggressive disease, while hepatitis C patients have underlying cirrhosis and diabetes. The study highlights the need to consider hepatitis status when developing treatment plans for newly diagnosed patients.
Researchers at The University of Texas MD Anderson Cancer Center found that blocking FGL2 protein could potentially treat brain cancer. By modulating the immune system's checkpoints, FGL2 promotes tumor growth and suppresses the immune response.
Researchers discovered a direct link between telomere degeneration and myelodysplastic syndromes (MDS), a group of blood cell disorders. The study found that DNA damage caused by dysfunctional telomeres resulted in repressed expression of the RNA splicing gene SRSF2, affecting CMPs' ability to differentiate.
Researchers found that a toxic mushroom-based drug can suppress the POLR2A gene in cancer cells, resulting in complete tumor regression and reduced toxicity. The study's findings provide a new therapeutic approach for human cancers with common genomic alterations.
Researchers at MD Anderson Cancer Center found that CCAT2, a long non-coding RNA, regulates cancer metabolism in both human samples and animal models. This regulation appears to be linked to an increased risk of colon cancer, suggesting potential new targets for cancer treatment.
Researchers found that patients with anti-TP53 autoantibodies can detect ovarian cancer up to 13 months before rising CA125 levels. The study suggests a novel assay method for earlier detection of the disease.
Researchers from MD Anderson Cancer Center are part of two new Stand Up to Cancer Dream Teams focused on lung cancer driven by KRAS mutations and preventing high-risk ovarian cancer. The teams aim to test combination therapies and launch prevention efforts.
Researchers at MD Anderson Cancer Center have uncovered a novel mechanism by which the tumor suppressor gene p53 regulates PD-L1, allowing non-small cell lung cancer to grow. MicroRNA delivery with existing treatments may represent a new therapeutic approach for lung cancer.
Researchers at MD Anderson Cancer Center identified three subsets of lung cancer with KRAS gene mutations, each with unique signaling patterns and susceptibility to different therapeutic strategies. These subsets may offer new approaches for treating lung adenocarcinoma, the most common form of lung cancer.
James Allison, a renowned immunologist, has been recognized for his pioneering discovery that blocking CTLA-4 improves antitumor immune responses. His work led to the development of ipilimumab, an immune checkpoint inhibitor that transformed melanoma treatment.